Zai Lab
Nicole Tong has over 20 years of work experience, with their most recent role as VP Commercial Finance at Zai Lab since December 2019. Prior to that, they worked at AstraZeneca in various finance roles, including Executive Finance Director and Finance Director, FP&A. Before that, they were Finance Director at McDonald's and Head Business Finance at Ciba Specialty Chemicals. Nicole also held positions at Ciba as Regional Head of Internal Auditing and Business Controller for Region China. Nicole began their career as an Auditor at Arthur Andersen & Co.
Nicole Tong obtained a Bachelor of Science degree in Accounting from Fudan University, where they studied from 1993 to 1997. Nicole also holds additional certifications, including the CIA (Certified Internal Auditor) from The Institute of Internal Auditors Inc., and the CPA China and CPA Canada designations obtained in 1998.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.